Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts

Journal of Rheumatology

Volumn 36, Issue 8, 2009, Pages 1580-1589

  Horiuchi, Marika ^a   Morinobu, Akio ^a   Chin, Takaaki ^b   Sakai, Yoshitada ^b   Kurosaka, Masahiro ^b   Kumagai, Shunichi ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Histone deacetylase; Matrix metalloprotease; Rheumatoid arthritis; siRNA; Synovial fibroblast

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BETA ACTIN; BROXURIDINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; INTERSTITIAL COLLAGENASE; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROTEIN P16; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NICK END LABELING; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; STAINING; SYNOVIAL FIBROBLAST; SYNOVIUM; TECHNOLOGY; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; ARTHRITIS, RHEUMATOID; CELL COUNT; CELL DIVISION; CELLS, CULTURED; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HUMANS; MATRIX METALLOPROTEINASE 1; OSTEOARTHRITIS; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; SYNOVIAL MEMBRANE;

EID: 68849105560     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081115     Document Type: Article

References (44)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
3. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000;2:361-7.
4. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 1989;83:1267-76.
5. Westhoff CS, Freudiger D, Petrow P, et al. Characterization of collagenase 3 (matrix metalloproteinase 13) messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum 1999;42:1517-27.
6. Yasuda T. Cartilage destruction by matrix degradation products. Modern Rheumatology 2006;16:197-205.
7. Rannou F, Francois M, Corvol MT, Berenbaum F. Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine 2006;73:29-36.
8. Berenbaum F. 'Rheumatoid chondritis' or the place of cartilage in rheumatoid inflammation. Br J Rheumatol 1998;37:4-6.
9. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80.
10. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
11. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev 2002;1:287-99.
12. Morinobu A, Wang B, Liu J, Yoshiya S, Kurosaka M, Kumagai S. Trichostatin A cooperates with Fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2006;33:1052-60.
13. Jungel A, Baresova V, Ospelt C, et al. Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis. Ann Rheum Dis 2006;65:910-2.
14. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003;8:707-17.
15. Nishida K, Komiyama T, Miyazawa S, et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum 2004;50:3365-76.
16. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52.
17. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31.
18. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Exp Opin Invest Drugs 2005;14:1497-511.
19. Bhaskara S, Chyla BJ, Amann JM, et al. Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. Mol Cell 2008;30:61-72.
20. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nature Rev 2006;5:769-84.
21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Yang WM, Inouye C, Zeng Y, Bearss D, Seto E. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Nat Acad Sci USA 1996;93:12845-50.
23. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996;272:408-11.
24. Montgomery RL, Davis CA, Potthoff MJ, et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007;21:1790-802.
25. Habold C, Poehlmann A, Bajbouj K, et al. Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J Cell Mol Med 2008;12:607-21.
26. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.
27. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177-89.
28. Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-4.
29. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Journal Biol Chem 2006;281:13548-58.
30. Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treatment 2005;94:11-6.
31. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-63.
32. Song J, Noh JH, Lee JH, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005;113:264-8.
33. Huber LC, Brock M, Hemmatazad H, et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum 2007;56:1087-93.
34. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Comm 2003;310:529-36.
35. Archer SY, Meng S, Shei A, Hodin RA. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Nat Acad Sci USA 1998;95:6791-6.
36. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Nat Acad Sci USA 2000;97:10014-9.
37. Herold C, Ganslmayer M, Ocker M, et al. The histone-deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002;36:233-40.
38. Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002;64:1079-90.
39. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63:4460-71.
40. Sawa H, Murakami H, Ohshima Y, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol 2001;18:109-14.
41. Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Current Opin Pharmacol 2003;3:317-22.
42. Ashburner BP, Westerheide SD, Baldwin AS Jr. The p65 (RelA) subunit of NF-kappa B interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001;21:7065-77.
43. Yun HJ, Yoo WH, Han MK, Lee YR, Kim JS, Lee SI. Epigallocatechin-3- gallate suppresses TNF-alpha-induced production of MMP-1 and -3 in rheumatoid arthritis synovial fibroblasts. Rheumatol Int 2008;29:23-9.
44. Kunisch E, Gandesiri M, Fuhrmann R, Roth A, Winter R, Kinne RW. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis 2007;66:1043-51.